Theresa Guo

Theresa Guo

Auto-generated profile, based on publicly available information

Theresa Guo

Department of Otolaryngology — Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
FGFrederico Omar Gleber-Netto
Frederico Omar Gleber-Netto
XRXiayu Rao
Xiayu Rao
TGTheresa Guo
Theresa Guo
YXYuanxin Xi
Yuanxin Xi
MGMeng Gao
Meng Gao
CPCurtis Pickering
Curtis Pickering
Incidence of HPV + oropharyngeal squamous cell carcinoma (OPSCC) has been increasing dramatically. Although long-term survival rates for these patients are high, they often suffer from permanent radiotherapy-related morbidity. This has prompted the development of de-escalation clinical protocols to reduce morbidity. However, a subset of patients do not respond even to standard therapy and have poor outcomes. It is unclear how to properly identify and treat the high- and low-risk HPV + OPSCC patients. Since HPV positivity drives radiotherapy sensitivity, we hypothesized that variations in HPV biology may cause differences in treatment response and outcome. By analyzing gene expression data, we identified variations in HPV-related molecules among HPV + OPSCC. A subset of tumors presented a molecular profile distinct from that of typical HPV + tumors and exhibited poor treatment response, indicating molecular and clinical similarities with HPV – tumors. These molecular changes were also observed in vitro and correlated with radiation sensitivity. Finally, we developed a prognostic biomarker signature for identification of this subgroup of HPV + OPSCC and validated it in independent cohorts of oropharyngeal and cervical carcinomas. These findings could translate to improved patient stratification for treatment deintensification and new therapeutic approaches for treatment-resistant HPV-related cancer.

1 July 2015 in Surgical Oncology Clinics of North America
Verified
Journal Article
Closed access
TGTheresa Guo
Theresa Guo
JCJoseph A. Califano
Joseph A. Califano

5 December 2016 in bioRxiv
Verified
Preprint
Open access
PDF file
BABahman Afsari
Bahman Afsari
TGTheresa Guo
Theresa Guo
MCMichael Considine
Michael Considine
Liliana D. FloreaLiliana D. Florea
Liliana D. Florea
LKLuciane Kagohara
Luciane Kagohara
EFElana J. Fertig
Elana J. Fertig
Motivation: Current bioinformatics methods to detect changes in gene isoform usage in distinct phenotypes compare the relative expected isoform usage in phenotypes. These statistics model differences in isoform usage in normal tissues, which have stable regulation of gene splicing. Pathological conditions, such as cancer, can have broken regulation of splicing that increases the heterogeneity of the expression of splice variants. Inferring events with such differential heterogeneity in gene isoform usage requires new statistical approaches. Results: We introduce Splice Expression Variability Analysis (SEVA) to model increased heterogeneity of splice variant usage between conditions (e.g., tumor and normal samples). SEVA uses a rank-based multivariate statistic that compares the variability of junction expression profiles within one condition to the variability within another. Simulated data show that SEVA is unique in modeling heterogeneity of gene isoform usage, and benchmark SEVA’s performance against EBSeq, DiffSplice, and rMATS that model differential isoform usage instead of heterogeneity. We confirm the accuracy of SEVAin identifying known splice variants in head and neck cancer and perform cross-study validation of novel splice variants. A novel comparison of splice variant heterogeneity between subtypes of head and neck cancer demonstrated unanticipated similarity between the heterogeneity of gene isoform usage in HPV-positive and HPV-negative subtypes and anticipated increased heterogeneity among HPV-negative samples with mutations in genes that regulate the splice variant machinery. Conclusion: These results show that SEVA accurately models differential heterogeneity of gene isoform usage from RNA-seq data. Availability: SEVA is implemented in the R/Bioconductor package GSReg. Contact: bahman@jhu.edu , favorov@sensi.org , ejfertig@jhmi.edu